Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
"A slow start for self-amplifying mRNA vaccines" was originally created and published by Pharmaceutical Technology, a ...
a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The primary objective of this ...
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
Arcturus’ lead clinical stage product candidates include a first-in-class, self-amplifying mRNA vaccine for COVID-19 and an mRNA replacement therapy for ornithine transcarbamylase (OTC ...
Japan is the first country to put a self-amplifying mRNA vaccine into practical use. The health ministry’s expert committee that approved the replicon vaccine has said, “It is desirable to ...
In contrast, saRNA delivered into a cell first self-amplifies, resulting in very high mRNA copy numbers, thereby achieving superior gene expression and an amplified protein response with a much ...
A significant breakthrough in RNA therapeutics, this self-amplifying technology overcomes ... efficacy at 100X lower doses than conventional mRNA. "This advancement solves a longstanding challenge ...
Five types of vaccines are available, and the list includes, for the first time, a new type of mRNA vaccine that uses a self-amplifying RNA (saRNA) technology called “replicon," manufactured by ...